Table 1.

Newly diagnosed primary LGG patient characteristics, imputed data (TCGA 1994–2013, OBTS 2007–2018)

	TCGA (N = 238)	OBTS (N = 98)	P-value
Tumor grade,* N (%)			0.190
Grade II	118 (49.6)	57 (58.2)
Grade III	120 (50.4)	41 (41.8)
Year of diagnosis,* N (%)			<0.001
1994	2 (0.8)	0 (0.0)
1995	3 (1.3)	0 (0.0)
1996	1 (0.4)	0 (0.0)
1997	3 (1.3)	0 (0.0)
1998	9 (3.8)	0 (0.0)
1999	3 (1.3)	0 (0.0)
2000	4 (1.7)	0 (0.0)
2001	5 (2.1)	0 (0.0)
2002	0 (0.0)	0 (0.0)
2003	2 (0.8)	0 (0.0)
2004	1 (0.4)	0 (0.0)
2005	7 (2.9)	0 (0.0)
2006	14 (5.9)	0 (0.0)
2007	13 (5.5)	4 (4.1)
2008	20 (8.4)	9 (9.2)
2009	23 (9.7)	12 (12.2)
2010	28 (11.8)	5 (5.1)
2011	50 (21.0)	18 (18.4)
2012	44 (18.5)	8 (8.2)
2013	6 (2.5)	14 (14.3)
2014	0 (0.0)	10 (10.2)
2015	0 (0.0)	9 (9.2)
2016	0 (0.0)	5 (5.1)
2017	0 (0.0)	2 (2.0)
2018	0 (0.0)	2 (2.0)
Age at diagnosis,^ y, mean (SD)	42.46 (13.27)	47.69 (16.58)	0.002
Sex,* N (%)			1.000
Male	132 (55.5)	55 (56.1)
Female	106 (44.5)	43 (43.9)
Race,* N (%)	(MIissing = 4; 1.7)		0.107
White	224 (95.7)	90 (91.8)
Black	9 (3.8)	6 (6.1)
American Indian/Alaska Native	1 (0.4)	0 (0.0)
Asia/Pacific Islander	0 (0.0)	2 (2.0)
KPS* (imputed),* N (%)			<0.001
40	1 (0.4)	2 (2.0)
50	4 (1.7)	10 (10.2)
60	7 (2.9)	9 (9.2)
70	21 (8.8)	14 (14.3)
80	41 (17.2)	14 (14.3)
90	106 (44.5)	36 (36.7)
100	58 (24.4)	13 (13.3)
First presenting symptom,* N (%)	(Missing = 20; 8.4)		0.229
Seizures	116 (53.2)	60 (61.2)
Other	102 (46.8)	38 (38.8)
Molecular subtype,* N (%)			<0.001
IDHmut-codel	65 (27.3)	30 (30.6)
IDHmut-non-codel	125 (52.5)	29 (29.6)
IDHwt	48 (20.2)	39 (39.8)
Follow-up months,# median [interquartile range]	20.70 [7.18, 40.93]	43.29 [16.73, 82.92]	<0.001
Survival status,* N (%)			<0.001
Alive	178 (74.8)	53 (54.1)
Dead	60 (25.2)	45 (45.9)

*P-value calculated by chi-square test.

^P-value calculated by t-test.

#P-value calculated by Wilcoxon rank-sum test.